U-NEURON BIOMEDICAL INC.
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
State-level Storage Equipment and Technology
U-NEURON BIOMEDICAL is devoted to the development of stem cell isolation, storage and clinical applications. It owns the Patent on the Technology of Isolation and Culture of Amniotic Fluid Stem Cell, and has si
U-NEURON BIOMEDICAL is devoted to the development of stem cell isolation, storage and clinical applications. It owns the Patent on the Technology of Isolation and Culture of Amniotic Fluid Stem Cell, and has si
The content above was translated by Ai
Founded Year
2015
Unified Business No.
54867417
Status
Active
Number of Employees
30
Total Paid-in
Capital
408,030,000 (NT$)
Location of Company
Taiwan
, New Taipei City
Exit Status
Emerging Stock Exchange(2023)
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
U-NEURON GROUP is committed to advancing the real value of regenerative medicine by popularizing cell therapy and related products to improve human life. The group consists of U-NEURON BIOMEDICAL CO., LTD., specializing in cell therapy technology R&D, and UAF BIOMEDICAL, which owns ExoCare, a leading brand in medical aesthetics.
Chairman’s Message
U-NEURON GROUP aims to develop innovative cell therapy technologies and become Taiwan’s first professional amniotic fluid stem cell storage organization. By leveraging the group’s expertise, the company seeks to address unmet medical needs through advanced R&D, offer effective treatment options, and build accessible, trustworthy brands in medical beauty and regenerative medicine.
Expertise in Amniotic Fluid Stem Cells
Founded in 2015, U-NEURON BIOMEDICAL focuses on stem cell research and clinical applications. The company collaborates with top medical and academic institutions including the Bioresource Collection and Research Center, National Yang-Ming University, Taipei Veterans General Hospital, Cathay General Hospital, Linkou Chang Gung Memorial Hospital, and China Medical University Hospital.
Currently, the company’s main work centers on stem cell storage and clinical trials. It has submitted an application for a Phase II clinical trial using autologous stem cell transplantation to treat stroke. Notably, U-NEURON BIOMEDICAL is the first company in Taiwan to receive a U.S. patent for the culture and isolation of amniotic fluid stem cells.
Chairman’s Message
U-NEURON GROUP aims to develop innovative cell therapy technologies and become Taiwan’s first professional amniotic fluid stem cell storage organization. By leveraging the group’s expertise, the company seeks to address unmet medical needs through advanced R&D, offer effective treatment options, and build accessible, trustworthy brands in medical beauty and regenerative medicine.
Expertise in Amniotic Fluid Stem Cells
Founded in 2015, U-NEURON BIOMEDICAL focuses on stem cell research and clinical applications. The company collaborates with top medical and academic institutions including the Bioresource Collection and Research Center, National Yang-Ming University, Taipei Veterans General Hospital, Cathay General Hospital, Linkou Chang Gung Memorial Hospital, and China Medical University Hospital.
Currently, the company’s main work centers on stem cell storage and clinical trials. It has submitted an application for a Phase II clinical trial using autologous stem cell transplantation to treat stroke. Notably, U-NEURON BIOMEDICAL is the first company in Taiwan to receive a U.S. patent for the culture and isolation of amniotic fluid stem cells.
The content above was translated by Ai
